HbA1c blood test is commonly used in many healthcare organizations to test a patient for diabetes, both type 1 and type 2. HbA1c test kits allow convenient and semi-quantitative testing of whole blood for glycated hemoglobin (HbA1c). As per the market research report, the rising incidence of diabetes is a major driver for the HbA1c testing market.
With growing awareness about prevention and management of diabetes, the report predicts that the demand for HbA1c testing devices will rise rapidly, especially in the Asia-Pacific, Latin America, MiddleEast and African regions. The market is segmented on the basis of end users, technologies, and geography.
- Based on end-use, this global market is divided into two segments, namely' laboratory testing and point-of-care (POC) testing devices. While lab testing devices held the majority share of the market in 2012, the global market for point-of-care testing devices is expected to grow at a faster pace during the forecast period.
- The technology segment of the market is divided into ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay and others (micro-optical detection method and capillary electrophoresis). Due to wide use of technology in device manufacturing, the affinity binding chromatography segment dominated the market in 2015. It is predicted that affinity binding chromatography will generate new opportunities in the forecast period.
- Geographically, the market is divided into North America, Asia Pacific, Europe, and Rest of the World. In terms of revenue, the market was dominated by North America In 2012. It is expected that the presence of modern healthcare infrastructure will propel the North America market for hemoglobin A1c testing devices in the years to come.
With the introduction of innovative hemoglobin A1c testing devices from the new entrants, the market is expected to be more competitive for the leading players. Leading companies operating in the global market include Abbott Laboratories, Arkray, Inc., Danaher Corporation, Siemens Healthcare, Trinity Biotech plc, Alere, Inc., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd.